2023

ABL-class Genomic Breakpoint Q-PCR: A Patient-specific Approach for MRD Monitoring in Acute Lymphoblastic Leukemia
van Outersterp I, van der Velden V, Hoogeveen P, Vaitkevičienė G, Sonneveld E, van Haaften G, Kuiper R, Zur Stadt U, Escherich G, Boer J, den Boer M
HEMASPHERE. 2023;7(10):e967.

2022

Clofarabine increases the eradication of minimal residual disease of primary B-precursor acute lymphoblastic leukemia compared to high-dose cytarabine without improvement of outcome. Results from the randomized clinical trial 08-09 of the Cooperative Acute Lymphoblastic Leukemia Study Group
Escherich G, Zur Stadt U, Borkhardt A, Dilloo D, Faber J, Feuchtinger T, Imschweiler T, Jorch N, Pekrun A, Schmid I, Schramm F, Spohn M, Zimmermann M, Horstmann M
HAEMATOLOGICA. 2022;107(5):1026-1033.

Amsacrine combined with etoposide and methylprednisolone is a feasible and safe component in first-line intensified treatment of pediatric patients with high-risk acute lymphoblastic leukemia in CoALL08-09 trial
Mezger K, Ebert S, Muhle H, Stadt U, Borkhardt A, Dilloo D, Faber J, Feuchtinger T, Imschweiler T, Jorch N, Pekrun A, Schmid I, Schramm F, Zimmermann M, Horstmann M, Escherich G
PEDIATR BLOOD CANCER. 2022;69(12):.

Characterization of IG-MYC-breakpoints and their application for quantitative minimal disease monitoring in high-risk pediatric Burkitt-lymphoma and -leukemia
Möker P, Zur Stadt U, Zimmermann M, Alawi M, Mueller S, Finger J, Knörr F, Riquelme A, Oschlies I, Klapper W, Bradtke J, Burkhardt B, Woessmann W, Damm-Welk C
LEUKEMIA. 2022;36(9):2343-2346.

2021

Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: a matched cohort study
Michels N, Boer J, Enshaei A, Sutton R, Heyman M, Ebert S, Fiocco M, de Groot-Kruseman H, van der Velden V, Barbany G, Escherich G, Vora A, Trahair T, Dalla-Pozza L, Pieters R, Zur Stadt U, Schmiegelow K, Moorman A, Zwaan C, den Boer M
LANCET HAEMATOL. 2021;8(10):e700-e710.

2020

Functional flow cytometry of monocytes for routine diagnosis of innate primary immunodeficiencies
Ammann S, Fuchs S, Martin-Martin L, Castro C, Spielberger B, Klemann C, Elling R, Heeg M, Speckmann C, Hainmann I, Kaiser-Labusch P, Horneff G, Thalhammer J, Bredius R, Stadt U, Lehmberg K, Fuchs I, von Spee-Mayer C, Henneke P, Ehl S
J ALLERGY CLIN IMMUN. 2020;145(1):434-437.e4.

Ulceration in Prolidase Deficiency: Successful Treatment with Anticoagulants
Süßmuth K, Metze D, Muresan A, Lehmberg K, Zur Stadt U, Speckmann C, Park J, Marquardt T, Oji V, Goerge T
ACTA DERM-VENEREOL. 2020;100(1):adv00002.

2019

Pediatric ALL relapses after allo-SCT show high individuality, clonal dynamics, selective pressure, and druggable targets
Hoell J, Ginzel S, Kuhlen M, Kloetgen A, Gombert M, Fischer U, Hein D, Demir S, Stanulla M, Schrappe M, Zur Stadt U, Bader P, Babor F, Schuster F, Strahm B, Alten J, Moericke A, Escherich G, von Stackelberg A, Thiele R, McHardy A, Peters C, Bornhauser B, Bourquin J, Krause S, Enczmann J, Meyer L, Eckert C, Borkhardt A, Meisel R
BLOOD ADV. 2019;3(20):3143-3156.

High sensitivity and clonal stability of the genomic fusion as single marker for response monitoring in ETV6-RUNX1-positive acute lymphoblastic leukemia
Hoffmann J, Krumbholz M, Gutiérrez H, Fillies M, Szymansky A, Bleckmann K, Zur Stadt U, Köhler R, Kuiper R, Horstmann M, von Stackelberg A, Eckert C, Metzler M
PEDIATR BLOOD CANCER. 2019;66(8):e27780.

IKZF1 Deletions with COBL Breakpoints Are Not Driven by RAG-Mediated Recombination Events in Acute Lymphoblastic Leukemia
Lopes B, Meyer C, Barbosa T, Poubel C, Mansur M, Duployez N, Bashton M, Harrison C, Zur Stadt U, Horstmann M, Pombo-de-Oliveira M, Palmi C, Cazzaniga G, Venn N, Sutton R, Alonso C, Tsaur G, Gupta S, Bakhshi S, Marschalek R, Emerenciano M
TRANSL ONCOL. 2019;12(5):726-732.

Results of CoALL 07-03 study childhood ALL based on combined risk assessment by in vivo and in vitro pharmacosensitivity
Schramm F, Zur Stadt U, Zimmermann M, Jorch N, Pekrun A, Borkhardt A, Imschweiler T, Christiansen H, Faber J, Schmid I, Feuchtinger T, Beron G, den Boer M, Pieters R, Horstmann M, Janka-Schaub G, Escherich G
BLOOD ADV. 2019;3(22):3688-3699.

Characterization of novel, recurrent genomic rearrangements as sensitive MRD targets in childhood B-cell precursor ALL
Zur Stadt U, Alawi M, Adao M, Indenbirken D, Escherich G, Horstmann M
BLOOD CANCER J. 2019;9(12):96.

2018

Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies
Cazzaniga G, De Lorenzo P, Alten J, Röttgers S, Hancock J, Saha V, Castor A, Madsen H, Gandemer V, Cavé H, Leoni V, Köhler R, Ferrari G, Bleckmann K, Pieters R, van der Velden V, Stary J, Zuna J, Escherich G, Stadt U, Aricò M, Conter V, Schrappe M, Valsecchi M, Biondi A
HAEMATOLOGICA. 2018;103(1):107-115.

Is an infectious trigger always required for primary hemophagocytic lymphohistiocytosis? Lessons from in utero and neonatal disease
Heeg M, Ammann S, Klemann C, Panning M, Falcone V, Hengel H, Lehmberg K, Zur Stadt U, Wustrau K, Janka G, Ehl S
PEDIATR BLOOD CANCER. 2018;65(11):e27344.

2017

Primary and secondary hemophagocytic lymphohistiocytosis have different patterns of T-cell activation, differentiation and repertoire
Ammann S, Lehmberg K, Zur Stadt U, Janka-Schaub G, Rensing-Ehl A, Klemann C, Heeg M, Bode S, Fuchs I, Ehl S
EUR J IMMUNOL. 2017;47(2):364-373.

Effective Immunological Guidance of Genetic Analyses Including Exome Sequencing in Patients Evaluated for Hemophagocytic Lymphohistiocytosis
Ammann S, Lehmberg K, Zur Stadt U, Klemann C, Bode S, Speckmann C, Janka G, Wustrau K, Rakhmanov M, Fuchs I, Hennies H, Ehl S
J CLIN IMMUNOL. 2017;37(8):770-780.

The role of constitutive activation of FMS-related tyrosine kinase-3 andmutational status in infants with-rearranged acute lymphoblastic leukemia
Fedders H, Alsadeq A, Schmäh J, Vogiatzi F, Zimmermann M, Möricke A, Lenk L, Stadt U, Horstmann M, Pieters R, Schrappe M, Stanulla M, Cario G, Schewe D
HAEMATOLOGICA. 2017;102(11):e438-e442.

Hemophagocytic lymphohistiocytosis as presenting manifestation of profound combined immunodeficiency due to an ORAI1 mutation
Klemann C, Ammann S, Heizmann M, Fuchs S, Bode S, Heeg M, Fuchs H, Lehmberg K, Zur Stadt U, Roll C, Vraetz T, Speckmann C, Lorenz M, Schwarz K, Rohr J, Feske S, Ehl S
J ALLERGY CLIN IMMUN. 2017;140(6):1721-1724.

Genomic and transcriptional landscape of P2RY8-CRLF2-positive childhood acute lymphoblastic leukemia
Vesely C, Frech C, Eckert C, Cario G, Mecklenbräuker A, Zur Stadt U, Nebral K, Kraler F, Fischer S, Attarbaschi A, Schuster M, Bock C, Cavé H, von Stackelberg A, Schrappe M, Horstmann M, Mann G, Haas O, Panzer-Grümayer R
LEUKEMIA. 2017;31(7):1491-1501.

Lineage switch under blinatumomab treatment of relapsed common acute lymphoblastic leukemia without MLL rearrangement
Zoghbi A, Zur Stadt U, Winkler B, Müller I, Escherich G
PEDIATR BLOOD CANCER. 2017;64(11):11.

2016

Mutations in AP3D1 associated with immunodeficiency and seizures define a new type of Hermansky-Pudlak syndrome
Ammann S, Schulz A, Krägeloh-Mann I, Dieckmann N, Niethammer K, Fuchs S, Eckl K, Plank R, Werner R, Altmüller J, Thiele H, Nürnberg P, Bank J, Strauss A, von Bernuth H, Zur Stadt U, Grieve S, Griffiths G, Lehmberg K, Hennies H, Ehl S
BLOOD. 2016;127(8):997-1006.

COBL is a novel hotspot for IKZF1 deletions in childhood acute lymphoblastic leukemia
Lopes B, Meyer C, Barbosa T, Stadt U, Horstmann M, Venn N, Heatley S, White D, Sutton R, Pombo-de-Oliveira M, Marschalek R, Emerenciano M
ONCOTARGET. 2016;7(33):53064-53073.

Rapid Capture Next-Generation Sequencing in Clinical Diagnostics of Kinase Pathway Aberrations in B-Cell Precursor ALL
Stadt U, Escherich G, Indenbirken D, Alawi M, Adao M, Horstmann M
PEDIATR BLOOD CANCER. 2016;63(7):1283-6.

2015

Novel Patient with Late-Onset Familial Hemophagocytic Lymphohistiocytosis with STXBP2 Mutations Presenting with Autoimmune Hepatitis, Neurological Manifestations and Infections Associated with Hypogammaglobulinemia
Esmaeilzadeh H, Bemanian M, Nabavi M, Arshi S, Fallahpour M, Fuchs I, Zur Stadt U, Warnatz K, Ammann S, Ehl S, Lehmberg K, Rezaei N
J CLIN IMMUNOL. 2015;35(1):22-25.

Late-onset hemophagocytic lymphohistiocytosis (HLH) in an adult female with Griscelli syndrome type 2 (GS2)
Henkes M, Finke J, Warnatz K, Ammann S, Stadt U, Janka-Schaub G, Brugger W
ANN HEMATOL. 2015;94(6):1057-60.

Malignancy-associated haemophagocytic lymphohistiocytosis in children and adolescents
Lehmberg K, Sprekels B, Nichols K, Woessmann W, Müller I, Suttorp M, Bernig T, Beutel K, Bode S, Kentouche K, Kolb R, Längler A, Minkov M, Schilling F, Schmid I, Vieth S, Ehl S, Zur Stadt U, Janka G
BRIT J HAEMATOL. 2015;170(4):539-49.

KRAS and CREBBP mutations: a relapse-linked malicious liaison in childhood high hyperdiploid acute lymphoblastic leukemia
Malinowska-Ozdowy K, Frech C, Schönegger A, Eckert C, Cazzaniga G, Stanulla M, Zur Stadt U, Mecklenbräuker A, Schuster M, Kneidinger D, von Stackelberg A, Locatelli F, Schrappe M, Horstmann M, Attarbaschi A, Bock C, Mann G, Haas O, Panzer-Grümayer R
LEUKEMIA. 2015;29(8):1656-1667.

2014

A new functional assay for the diagnosis of X-linked inhibitor of apoptosis (XIAP) deficiency
Ammann S, Elling R, Gyrd-Hansen M, Dückers G, Bredius R, Burns S, Edgar J, Worth A, Brandau H, Warnatz K, Zur Stadt U, Hasselblatt P, Schwarz K, Ehl S, Speckmann C
CLIN EXP IMMUNOL. 2014;176(3):394-400.

2013

Disease-causing mutations in the XIAP BIR2 domain impair NOD2-dependent immune signalling
Damgaard R, Fiil B, Speckmann C, Yabal M, zur Stadt U, Bekker-Jensen S, Jost P, Ehl S, Mailand N, Gyrd-Hansen M
EMBO MOL MED. 2013;5(8):1278-95.

Syntaxin 11 is required for NK and CD8⁺ T-cell cytotoxicity and neutrophil degranulation.
D'Orlando O, Zhao F, Kasper B, Orinska Z, Müller J, Hermans-Borgmeyer I, Griffiths G, Zur Stadt U, Bulfone-Paus S
EUR J IMMUNOL. 2013;43(1):194-208.

Clofarabine in combination with pegylated asparaginase in the frontline treatment of childhood acute lymphoblastic leukaemia: a feasibility report from the CoALL 08-09 trial
Escherich G, Zur Stadt U, Zimmermann M, Horstmann M
BRIT J HAEMATOL. 2013;163(2):240-7.

The risk of hemophagocytic lymphohistiocytosis in Hermansky-Pudlak syndrome type 2
Jessen B, Bode S, Ammann S, Chakravorty S, Davies G, Diestelhorst J, Frei-Jones M, Gahl W, Gochuico B, Griese M, Griffiths G, Janka-Schaub G, Klein C, Kögl T, Kurnik K, Lehmberg K, Maul-Pavicic A, Mumford A, Pace D, Parvaneh N, Rezaei N, de Saint Basile G, Schmitt-Graeff A, Schwarz K, Karasu G, Zieger B, zur Stadt U, Aichele P, Ehl S
BLOOD. 2013;121(15):2943-51.

Hemophagocytic lymphohistiocytosis in syntaxin-11-deficient mice: T-cell exhaustion limits fatal disease
Kögl T, Müller J, Jessen B, Schmitt-Graeff A, Janka-Schaub G, Ehl S, zur Stadt U, Aichele P
BLOOD. 2013;121(4):604-13.

The MLL recombinome of acute leukemias in 2013
Meyer C, Hofmann J, Burmeister T, Gröger D, Park T, Emerenciano M, Pombo de Oliveira M, Renneville A, Villarese P, Macintyre E, Cavé H, Clappier E, Mass-Malo K, Zuna J, Trka J, De Braekeleer E, De Braekeleer M, Oh S, Tsaur G, Fechina L, van der Velden V, van Dongen J, Delabesse E, Binato R, Silva M, Kustanovich A, Aleinikova O, Harris M, Lund-Aho T, Juvonen V, Heidenreich O, Vormoor J, Choi W, Jarosova M, Kolenova A, Bueno C, Menendez P, Wehner S, Eckert C, Talmant P, Tondeur S, Lippert E, Launay E, Henry C, Ballerini P, Lapillone H, Callanan M, Cayuela J, Herbaux C, Cazzaniga G, Kakadiya P, Bohlander S, Ahlmann M, Choi J, Gameiro P, Lee D, Krauter J, Cornillet-Lefebvre P, Te Kronnie G, Schäfer B, Kubetzko S, Alonso C, zur Stadt U, Sutton R, Venn N, Izraeli S, Trakhtenbrot L, Madsen H, Archer P, Hancock J, Cerveira N, Teixeira M, Lo Nigro L, Möricke A, Stanulla M, Schrappe M, Sedék L, Szczepański T, Zwaan C, Coenen E, van den Heuvel-Eibrink M, Strehl S, Dworzak M, Panzer-Grümayer R, Dingermann T, Klingebiel T, Marschalek R
LEUKEMIA. 2013;27(11):2165-76.

Refinement of IKZF1 recombination hotspots in pediatric BCP-ALL patients.
Meyer C, Zur Stadt U, Escherich G, Hofmann J, Binato R, Barbosa T, Emerenciano M, Pombo-de-Oliveira M, Horstmann M, Marschalek R
AM J BLOOD RES. 2013;3(2):165-173.

X-linked inhibitor of apoptosis (XIAP) deficiency: the spectrum of presenting manifestations beyond hemophagocytic lymphohistiocytosis
Speckmann C, Lehmberg K, Albert M, Damgaard R, Fritsch M, Gyrd-Hansen M, Rensing-Ehl A, Vraetz T, Grimbacher B, Salzer U, Fuchs I, Ufheil H, Belohradsky B, Hassan A, Cale C, Elawad M, Strahm B, Schibli S, Lauten M, Kohl M, Meerpohl J, Rodeck B, Kolb R, Eberl W, Soerensen J, von Bernuth H, Lorenz M, Schwarz K, zur Stadt U, Ehl S
CLIN IMMUNOL. 2013;149(1):133-41.

Persistent defective membrane trafficking in epithelial cells of patients with familial hemophagocytic lymphohistiocytosis type 5 due to STXBP2/MUNC18-2 mutations
Stepensky P, Bartram J, Barth T, Lehmberg K, Walther P, Amann K, Philips A, Beringer O, zur Stadt U, Schulz A, Amrolia P, Weintraub M, Debatin K, Hoenig M, Posovszky C
PEDIATR BLOOD CANCER. 2013;60(7):1215-22.

2012

Recent advances in the diagnosis and treatment of hemophagocytic lymphohistiocytosis.
Bode S, Lehmberg K, Maul-Pavicic A, Vraetz T, Janka-Schaub G, Zur Stadt U, Ehl S
ARTHRITIS RES THER. 2012;14(3):213.

A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes.
Bryceson Y, Pende D, Maul-Pavicic A, Gilmour K, Ufheil H, Vraetz T, Chiang S, Marcenaro S, Meazza R, Bondzio I, Walshe D, Janka-Schaub G, Lehmberg K, Beutel K, Zur Stadt U, Binder N, Arico M, Moretta L, Henter J, Ehl S
BLOOD. 2012;119(12):2754-2763.

Distinct mutations in STXBP2 are associated with variable clinical presentations in patients with familial hemophagocytic lymphohistiocytosis type 5 (FHL5)
Pagel J, Beutel K, Lehmberg K, Koch F, Maul-Pavicic A, Rohlfs A, Al-Jefri A, Beier R, Lilian B, Ehlert K, Gross-Wieltsch U, Jorch N, Kremens B, Pekrun A, Sparber-Sauer M, Mejstrikova E, Wawer A, Ehl S, Zur Stadt U, Janka-Schaub G
BLOOD. 2012;119(25):6016-6024.

Fatal EBV infection and variable clinical manifestations in an XLP-1 pedigree - rapid diagnosis of primary immunodeficiencies may save lives.
Sperl D, Benesch M, Urban C, Lackner H, Sovinz P, Speicher M, Uhrig S, Schwarzbraun T, Schwinger W, Zur Stadt U, Beutel K, Janka-Schaub G, Scarpatetti M, Seidel M
KLIN PADIATR. 2012;224(6):386-389.

In vivo imaging enables high resolution preclinical trials on patients' leukemia cells growing in mice.
Terziyska N, Catarina C, Groiss V, Schneider K, Farkasova K, Ogris M, Wagner E, Ehrhardt H, Brentjens R, Zur Stadt U, Horstmann M, Quintanilla-Martinez L, Jeremias I
PLOS ONE. 2012;7(12):52798.

Quantification of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL) using amplicon-fusion-site polymerase chain reaction (AFS-PCR).
Weber A, Taube S, Zur Stadt U, Horstmann M, Krohn K, Bradtke J, Teigler-Schlegel A, Leiblein S, Christiansen H
EXP HEMATOL ONCOL. 2012;1(1):33.

2011

The long-term impact of in vitro drug sensitivity on risk stratification and treatment outcome in acute lymphoblastic leukemia of childhood (CoALL 06-97).
Escherich G, Troeger A, Gobel U, Graubner U, Pekrun A, Jorch N, Kaspers G, Zimmermann M, Zur Stadt U, Kazemir K, Pieters R, Horstmann M, Denboer M, Janka-Schaub G
HAEMATOLOGICA. 2011;96(6):854-862.

Subtle differences in CTL cytotoxicity determine susceptibility to hemophagocytic lymphohistiocytosis in mice and humans with Chediak-Higashi syndrome.
Jessen B, Maul-Pavicic A, Ufheil H, Vraetz T, Enders A, Lehmberg K, Längler A, Gross-Wieltsch U, Bay A, Kaya Z, Bryceson Y, Koscielniak E, Badawy S, Davies G, Hufnagel M, Schmitt-Graeff A, Aichele P, Zur Stadt U, Schwarz K, Ehl S
BLOOD. 2011;118(17):4620-4629.

Genotype-phenotype study of familial haemophagocytic lymphohistiocytosis type 3.
Sieni E, Cetica V, Santoro A, Beutel K, Mastrodicasa E, Meeths M, Ciambotti B, Brugnolo F, Zur Stadt U, Pende D, Moretta L, Griffiths G, Henter J, Janka-Schaub G, Aricò M
J MED GENET. 2011;48(5):343-352.

2010

STXBP2 mutations in children with familial haemophagocytic lymphohistiocytosis type 5.
Cetica V, Santoro A, Gilmour K, Sieni E, Beutel K, Pende D, Marcenaro S, Koch F, Grieve S, Wheeler R, Zhao F, Zur Stadt U, Griffiths G, Aricò M
J MED GENET. 2010;47(9):595-600.

Profiling of histone H3 lysine 9 trimethylation levels predicts transcription factor activity and survival in acute myeloid leukemia.
Müller-Tidow C, Klein H, Hascher A, Isken F, Tickenbrock L, Thoennissen N, Agrawal-Singh S, Tschanter P, Disselhoff C, Wang Y, Becker A, Thiede C, Ehninger G, Zur Stadt U, Koschmieder S, Seidl M, Müller F, Schmitz W, Schlenke P, McClelland M, Berdel W, Dugas M, Serve H, Leukemia S
BLOOD. 2010;116(18):3564-3571.

Atypical familial hemophagocytic lymphohistiocytosis due to mutations in UNC13D and STXBP2 overlaps with primary immunodeficiency diseases
Rohr J, Beutel K, Maul-Pavicic A, Vraetz T, Thiel J, Warnatz K, Bondzio I, Gross-Wieltsch U, Schündeln M, Schütz B, Woessmann W, Groll A, Strahm B, Pagel J, Speckmann C, Janka-Schaub G, Griffiths G, Schwarz K, Zur Stadt U, Ehl S
HAEMATOLOGICA. 2010;95(12):2080-2087.

2009

Fatal Epstein-Barr virus infection in a case of familial hemophagocytic lymphohistiocytosis with syntaxin-11 mutation.
Albayrak M, Kaya Z, Yilmaz-Keskin E, Zur Stadt U, Koçak U, Gürsel T
TURKISH J PEDIATR. 2009;51(4):371-374.

Infection of T lymphocytes in Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children of non-Asian origin.
Beutel K, Gross-Wieltsch U, Wiesel T, Zur Stadt U, Janka-Schaub G, Wagner H
PEDIATR BLOOD CANCER. 2009;53(2):184-190.

Evaluation of SV40 in osteosarcoma and healthy population: a Hungarian-German study.
Heinsohn S, Szendroi M, Bielack S, Zur Stadt U, Kabisch H
ONCOL REP. 2009;21(2):289-297.

New insights to the MLL recombinome of acute leukemias.
Meyer C, Kowarz E, Hofmann J, Renneville A, Zuna J, Trka J, Ben Abdelali R, Macintyre E, De Braekeleer E, De Braekeleer M, Delabesse E, de Oliveira M, Cavé H, Clappier E, van Dongen J, Balgobind B, van den Heuvel-Eibrink M, Beverloo H, Panzer-Grümayer R, Teigler-Schlegel A, Harbott J, Kjeldsen E, Schnittger S, Koehl U, Gruhn B, Heidenreich O, Chan L, Yip S, Krzywinski M, Eckert C, Möricke A, Schrappe M, Alonso C, Schäfer B, Krauter J, Lee D, Zur Stadt U, Te Kronnie G, Sutton R, Izraeli S, Trakhtenbrot L, Lo Nigro L, Tsaur G, Fechina L, Szczepanski T, Strehl S, Ilencikova D, Molkentin M, Burmeister T, Dingermann T, Klingebiel T, Marschalek R
LEUKEMIA. 2009;23(8):1490-1499.

Molecular analysis and clinical aspects of four patients with Chédiak-Higashi syndrome (CHS).
Scherber E, Beutel K, Ganschow R, Schulz A, Janka-Schaub G, Zur Stadt U
CLIN GENET. 2009.

Patients with early relapse of primary hemophagocytic syndromes or with persistent CNS involvement may benefit from immediate hematopoietic stem cell transplantation.
Sparber-Sauer M, Hönig M, Schulz A, Zur Stadt U, Schütz C, Debatin K, Friedrich W
BONE MARROW TRANSPL. 2009;44(6):333-338.

Familial hemophagocytic lymphohistiocytosis type 5 (FHL-5) is caused by mutations in Munc18-2 and impaired binding to syntaxin 11
zur Stadt U, Rohr J, Seifert W, Koch F, Grieve S, Pagel J, Strauss J, Kasper B, Nürnberg G, Becker C, Maul-Pavicic A, Beutel K, Janka G, Griffiths G, Ehl S, Hennies H
AM J HUM GENET. 2009;85(4):482-492.

2008

Genotype-phenotype study of familial haemophagocytic lymphohistiocytosis due to perforin mutations.
Trizzino A, Zur Stadt U, Ueda I, Risma K, Janka G, Ishii E, Beutel K, Sumegi J, Cannella S, Pende D, Mian A, Henter J, Janka-Schaub G, Santoro A, Filipovich A, Aricò M
J MED GENET. 2008;45(1):15-21.

2007

DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia.
Agrawal S, Unterberg M, Koschmieder S, Zur Stadt U, Brunnberg U, Verbeek W, Büchner T, Berdel W, Serve H, Müller-Tidow C
CANCER RES. 2007;67(3):1370-1377.

Submicroscopic bone marrow involvement in isolated extramedullary relapses in childhood acute lymphoblastic leukemia: a more precise definition of "isolated" and its possible clinical implications, a collaborative study of the Resistant Disease Committee of the International BFM study group.
Hagedorn N, Acquaviva C, Fronkova E, von Stackelberg A, Barth A, Zur Stadt U, Schrauder A, Trka J, Gaspar N, Seeger K, Henze G, Cavé H, Eckert C
BLOOD. 2007;110(12):4022-4029.

Determination of the prognostic value of loss of heterozygosity at the retinoblastoma gene in osteosarcoma.
Heinsohn S, Evermann U, Zur Stadt U, Bielack S, Kabisch H
INT J ONCOL. 2007;30(5):1205-1214.

Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.
van der Velden V, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer E, Flohr T, Sutton R, Cave H, Madsen H, Cayuela J, Trka J, Eckert C, Foroni L, Zur Stadt U, Beldjord K, Raff T, van der Schoot C, van Dongen J
LEUKEMIA. 2007;21(4):604-611.

2006

Mutation spectrum in children with primary hemophagocytic lymphohistiocytosis: molecular and functional analyses of PRF1, UNC13D, STX11, and RAB27A.
Zur Stadt U, Beutel K, Kolberg S, Schneppenheim R, Kabisch H, Janka G, Hennies H
HUM MUTAT. 2006;27(1):62-68.

2005

DHPLC based fraction collection of TCR-gamma rearrangements in childhood ALL: direct sequencing of products amplified by a single or a multiplex PCR approach.
Zur Stadt U, Isbarn H, Schneppenheim R, Kabisch H
INT J ONCOL. 2005;27(2):547-552.

2003

Identification and characterisation of clonal incomplete T-cell-receptor Vdelta2-Ddelta3/Ddelta2-Ddelta3 rearrangements by denaturing high-performance liquid chromatography and subsequent fragment collection: implications for minimal residual disease monitoring in childhood acute lymphoblastic leukemia
zur Stadt U, Eckert C, Rischewski J, Michael K, Golta S, Müller M, Schneppenheim R, Kabisch H
J CHROMATOGR B. 2003;792(2):287-98.

2001

Denaturing HPLC for identification of clonal T-cell receptor gamma rearrangements in newly diagnosed acute lymphoblastic leukemia
zur Stadt U, Rischewski J, Schneppenheim R, Kabisch H
CLIN CHEM. 2001;47(11):2003-11.

Letzte Aktualisierung aus dem FIS: 23.12.2024 - 23:36 Uhr